163 related articles for article (PubMed ID: 31628978)
1. In vitro and human pharmacoscintigraphic evaluation of an oral 5-ASA delivery system for colonic release.
Foppoli A; Maroni A; Moutaharrik S; Melocchi A; Zema L; Palugan L; Cerea M; Gazzaniga A
Int J Pharm; 2019 Dec; 572():118723. PubMed ID: 31628978
[TBL] [Abstract][Full Text] [Related]
2. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers.
Brunner M; Lackner E; Exler PS; Fluiter HC; Kletter K; Tschurlovits M; Dudczak R; Eichler HG; Müller M
Aliment Pharmacol Ther; 2006 Jan; 23(1):137-44. PubMed ID: 16393291
[TBL] [Abstract][Full Text] [Related]
3. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
Lichtenstein GR; Kamm MA
Aliment Pharmacol Ther; 2008 Sep; 28(6):663-73. PubMed ID: 18532992
[TBL] [Abstract][Full Text] [Related]
4. Colon-specific prodrugs of 5-aminosalicylic acid: synthesis and in vitro/in vivo properties of acidic amino acid derivatives of 5-aminosalicylic acid.
Jung YJ; Lee JS; Kim YM
J Pharm Sci; 2001 Nov; 90(11):1767-75. PubMed ID: 11745734
[TBL] [Abstract][Full Text] [Related]
5. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
Christensen LA
Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
[TBL] [Abstract][Full Text] [Related]
6. Time- and pH-dependent colon-specific drug delivery for orally administered diclofenac sodium and 5-aminosalicylic acid.
Cheng G; An F; Zou MJ; Sun J; Hao XH; He YX
World J Gastroenterol; 2004 Jun; 10(12):1769-74. PubMed ID: 15188503
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery.
Turkoglu M; Ugurlu T
Eur J Pharm Biopharm; 2002 Jan; 53(1):65-73. PubMed ID: 11777754
[TBL] [Abstract][Full Text] [Related]
8. Xylan from Pineapple Stem Waste: a Potential Biopolymer for Colonic Targeting of Anti-inflammatory Agent Mesalamine.
Anindya AL; Oktaviani RD; Praevina BR; Damayanti S; Kurniati NF; Riani C; Rachmawati H
AAPS PharmSciTech; 2019 Feb; 20(3):112. PubMed ID: 30761441
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid.
Jung YJ; Lee JS; Kim YM
J Pharm Sci; 2000 May; 89(5):594-602. PubMed ID: 10756325
[TBL] [Abstract][Full Text] [Related]
10. [Ulcerative colitis--colon delivery of 5-aminosalicylic acid].
Muraoka M; Kimura G; Zhaopeng H; Takada K
Nihon Rinsho; 1998 Mar; 56(3):788-94. PubMed ID: 9549374
[TBL] [Abstract][Full Text] [Related]
11. In vivo efficacy of microbiota-sensitive coatings for colon targeting: a promising tool for IBD therapy.
Karrout Y; Dubuquoy L; Piveteau C; Siepmann F; Moussa E; Wils D; Beghyn T; Neut C; Flament MP; Guerin-Deremaux L; Dubreuil L; Deprez B; Desreumaux P; Siepmann J
J Control Release; 2015 Jan; 197():121-30. PubMed ID: 25445696
[TBL] [Abstract][Full Text] [Related]
12. In vitro degradation and drug-release properties of water-soluble chitosan cross-linked oxidized sodium alginate core-shell microgels.
Chen C; Liu M; Lii S; Gao C; Chen J
J Biomater Sci Polym Ed; 2012; 23(16):2007-24. PubMed ID: 21967992
[TBL] [Abstract][Full Text] [Related]
13. Preparation and evaluation of pectin-based colon-specific pulsatile capsule in vitro and in vivo.
Liu J; Zhang L; Jia Y; Hu W; Zhang J; Jiang H
Arch Pharm Res; 2012 Nov; 35(11):1927-34. PubMed ID: 23212634
[TBL] [Abstract][Full Text] [Related]
14. Validation of a pharmacokinetic model of colon-specific drug delivery and the therapeutic effects of chitosan capsules containing 5-aminosalicylic acid on 2,4,6-trinitrobenzenesulphonic acid-induced colitis in rats.
Tozaki H; Fujita T; Odoriba T; Terabe A; Okabe S; Muranishi S; Yamamoto A
J Pharm Pharmacol; 1999 Oct; 51(10):1107-12. PubMed ID: 10579681
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the in-vivo drug release from pellets film-coated with a dispersion of high amylose starch and ethylcellulose for potential colon delivery.
Freire C; Podczeck F; Ferreira D; Veiga F; Sousa J; Pena A
J Pharm Pharmacol; 2010 Jan; 62(1):55-61. PubMed ID: 20722999
[TBL] [Abstract][Full Text] [Related]
16. Preparation and in vitro evaluation of chitosan matrices for colonic controlled drug delivery.
Zambito Y; Di Colo G
J Pharm Pharm Sci; 2003; 6(2):274-81. PubMed ID: 12935439
[TBL] [Abstract][Full Text] [Related]
17. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.
D'Incà R; Paccagnella M; Cardin R; Pathak S; Baldo V; Giron MC; Sturniolo GC
World J Gastroenterol; 2013 Sep; 19(34):5665-70. PubMed ID: 24039359
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis.
Dubey R; Dubey R; Omrey P; Vyas SP; Jain SK
J Drug Target; 2010 Sep; 18(8):589-601. PubMed ID: 20088681
[TBL] [Abstract][Full Text] [Related]
19. Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid.
Xu M; Sun M; Qiao H; Ping Q; Elamin ES
Int J Pharm; 2014 Jul; 468(1-2):165-71. PubMed ID: 24746693
[TBL] [Abstract][Full Text] [Related]
20. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats.
Tozaki H; Odoriba T; Okada N; Fujita T; Terabe A; Suzuki T; Okabe S; Muranishi S; Yamamoto A
J Control Release; 2002 Jul; 82(1):51-61. PubMed ID: 12106976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
